XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Sales from Products

Sales of the Company’s products were as follows:

			Three Months Ended March 31,
			2022																		2021
($ in millions)			U.S.						Int’l						Total						U.S.						Int’l						Total
Pharmaceutical:
Oncology
Keytruda			$	2,779					$	2,030					$	4,809					$	2,181					$	1,718					$	3,899
Alliance revenue - Lynparza (1)			141						125						266						118						110						228
Alliance revenue - Lenvima (1)			156						71						227						85						44						130
Alliance revenue - Reblozyl (2)			27						25						52						—						—						—
Vaccines
Gardasil/Gardasil 9			418						1,042						1,460						313						604						917
ProQuad/M-M-R II/Varivax			371						99						470						333						117						449
RotaTeq			175						41						216						118						41						158
Pneumovax 23			118						55						173						73						99						171
Vaqta			29						7						36						25						9						34
Hospital Acute Care
Bridion			195						199						395						167						173						340
Prevymis			40						54						94						35						47						82
Primaxin			1						58						58						—						65						65
Noxafil			10						48						57						15						52						67
Cancidas			1						52						53						3						55						57
Dificid			49						3						52						25						2						27
Invanz			1						52						52						4						52						57
Zerbaxa			18						12						30						(2)						(6)						(8)
Cardiovascular
Alliance revenue - Adempas/Verquvo (3)			71						1						72						68						6						74
Adempas			—						61						61						—						55						55
Virology
Lagevrio			1,523						1,723						3,247						—						—						—
Isentress/Isentress HD			61						97						158						71						138						209
Neuroscience
Belsomra			20						48						69						18						61						79
Immunology
Simponi			—						186						186						—						214						214
Remicade			—						61						61						—						85						85
Diabetes
Januvia			325						454						779						348						461						809
Janumet			63						391						454						84						401						486
Other pharmaceutical (4)			181						339						520						212						341						554
Total Pharmaceutical segment sales			6,773						7,334						14,107						4,294						4,944						9,238
Animal Health:
Livestock			171						661						832						157						662						819
Companion Animals			302						348						650						280						319						599
Total Animal Health segment sales			473						1,009						1,482						437						981						1,418
Total segment sales			7,246						8,343						15,589						4,731						5,925						10,656
Other (5)			93						220						312						59						(88)						(29)
			$	7,339					$	8,563					$	15,901					$	4,790					$	5,837					$	10,627

U.S. plus international may not equal total due to rounding.

(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).

(2)    Alliance revenue for Reblozyl represents royalties and a payment received related to the achievement of a regulatory milestone (see Note 4).

(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).

(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.

(5)    Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales (including sales to Organon). Other for the three months ended March 31, 2022 and 2021 also includes $114 million and $56 million, respectively, related to upfront and contingent milestone payments received by Merck for out-licensing arrangements.

Consolidated Sales by Geographic Area

Consolidated sales by geographic area where derived are as follows:

			Three Months Ended March 31,
($ in millions)			2022						2021
United States			$	7,339					$	4,790
Europe, Middle East and Africa			4,359						3,237
China			1,143						721
Japan			989						629
Asia Pacific (other than China and Japan)			930						575
Latin America			607						500
Other			534						175
			$	15,901					$	10,627

Reconciliation of Segment Profits to Income before Taxes

A reconciliation of segment profits to Income from Continuing Operations Before Taxes is as follows:

			Three Months Ended March 31,
($ in millions)			2022						2021
Segment profits:
Pharmaceutical segment			$	9,501					$	6,589
Animal Health segment			585						572
Total segment profits			10,086						7,161
Other profits			194						(50)
Unallocated:
Interest income			7						11
Interest expense			(243)						(200)
Amortization			(699)						(514)
Depreciation			(378)						(340)
Research and development			(2,446)						(2,305)
Restructuring costs			(53)						(297)
Other unallocated, net			(1,607)						(479)
			$	4,861					$	2,987

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

+ Details

Name:	us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration